AI assistant
SYNTARA LIMITED — Share Issue/Capital Change 2021
Aug 25, 2021
65830_rns_2021-08-25_8d900de3-5804-45e3-adf9-e250de8c9aa6.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Application for quotation of +securities
==> picture [21 x 22] intentionally omitted <==
Announcement Summary
Entity name
PHARMAXIS LTD
Announcement Type
New announcement
Date of this announcement
Thursday August 26, 2021
The +securities to be quoted are:
+Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer
Total number of +securities to be quoted
| ASX +security | Number of +securities to | ||
|---|---|---|---|
| code | Security description | be quoted | Issue date |
| New code to be | ORDINARY FULLY PAID - NEW | 522,000 | 26/08/2021 |
| confirmed |
Refer to next page for full details of the announcement
Application for quotation of +securities
1 / 7
Application for quotation of +securities
==> picture [21 x 22] intentionally omitted <==
Part 1 - Entity and announcement details
1.1 Name of entity
PHARMAXIS LTD
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
1.2 Registered number type
ABN
Registration number 75082811630
1.3 ASX issuer code
PXS
1.4 The announcement is
==> picture [8 x 8] intentionally omitted <==
New announcement
1.5 Date of this announcement
26/8/2021
Application for quotation of +securities
2 / 7
Application for quotation of +securities
==> picture [21 x 22] intentionally omitted <==
Part 2 - Type of Issue
2.1 The +securities to be quoted are:
+Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer
2.2 The +securities to be quoted are:
==> picture [8 x 8] intentionally omitted <==
Additional +securities in a class that is already quoted on ASX ("existing class")
Application for quotation of +securities
3 / 7
Application for quotation of +securities
==> picture [21 x 22] intentionally omitted <==
Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B
Additional +securities to be quoted in an existing class issued under an +employee incentive scheme
FROM (Existing Class) ASX +security code and description
No security currently exists
FROM (Existing Class) +Security description
Issue of 522,000 ordinary shares under the Pharmaxis Employee Share Plan.
TO (Existing Class)
ASX +security code and description PXS : ORDINARY FULLY PAID
Please state the number of +securities issued under the +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer 522,000
Please provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms Pharmaxis Ltd Employee Share Plan Refer to the summary in the 2021 Annual report available at: https://www.pharmaxis. com.au/assets/Documents/pdf/02021/ASX/2021-08-12-Pharmaxis-Preliminary-Final-Statement-App-4E-FY21.pdf In summary terms, under the Pharmaxis Employee Share Plan, Pharmaxis issues up to $1,000 of fully paid Pharmaxis ordinary shares to eligible employees of the Group. The CEO and direct reports to the CEO do not participate in this plan. The ordinary shares have the same terms and rank equally with the existing ordinary shares. Subject to certain exceptions, the shares cannot be traded until the earlier of three years after the date of issue or 30 days after the relevant employee ceases to be an employee.
Are any of these +securities being issued to +key management personnel (KMP) or an +associate No
Issue date
26/8/2021
Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? No
If some of the issued +securities do not rank equally:
Application for quotation of +securities
4 / 7
Application for quotation of +securities
==> picture [21 x 22] intentionally omitted <==
Is the actual date from which the +securities will rank Provide the actual non-ranking end date equally (non-ranking end date) known? Yes 26/8/2024
Please state the extent to which the +securities do not rank equally: In relation to the next dividend, distribution or interest payment; or For any other reason
The ordinary shares rank equally in all respect with the existing ordinary shares except that the shares cannot be traded until the earlier of three years after the date of issue or 30 days after the relevant employee ceases to be an employee.
Issue details
Number of +securities to be quoted
522,000
Are the +securities being issued for a cash consideration?
==> picture [9 x 8] intentionally omitted <==
No
Please describe the consideration being provided for the +securities
Issue of 522,000 ordinary shares amongst 58 Australian employees of Pharmaxis in accordance with the Pharmaxis Employee Share Plan.
Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted
0.107900
Any other information the entity wishes to provide about the +securities to be quoted
Value of A$0.1079 per share. Nil consideration being paid by the relevant employees.
Application for quotation of +securities
5 / 7
Application for quotation of +securities
Part 4 - Issued capital following quotation
==> picture [21 x 22] intentionally omitted <==
Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)
4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)
| Total number of | |
|---|---|
| ASX +security code and description | +securities on issue |
| PXS : ORDINARY FULLY PAID | 453,571,039 |
| 4.2 Unquoted +securities (total number of each +class of +securities issued | but not quoted on ASX) |
| Total number of | |
| ASX +security code and description | +securities on issue |
| PXSAG : OPTION EXPIRING 28-JUN-2022 EX NIL PRICE | 92,000 |
| PXSAAP : OPTION EXPIRING 06-JUN-2023 EX NIL PRICE | 134,750 |
| PXSAAS : PERFORMANCE RIGHTS | 18,686,400 |
4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)
Application for quotation of +securities
6 / 7
Application for quotation of +securities
==> picture [21 x 22] intentionally omitted <==
Part 5 - Other Listing Rule requirements
5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? No
5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? No
5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? Yes
5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 522,000
5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No
Application for quotation of +securities
7 / 7